The modification of this ezrin peptide doubles the anti-inflammatory activity of RepG3 2× over Gepon, in a mouse dextran sulphate solution (DSS) gut inflammation model that mimics inflammatory bowel disease (IBD). Here, EZR is linked to inflammatory bowel disease.